Skip to main content

Takeda-Harrington Collaboration to Advance Rare Disease Therapeutics



From:    Jonathan S. Stamler, MD
              President, Harrington Discovery Institute
              Director, Institute for Transformative Molecular Medicine
              University Hospitals and Case Western Reserve University School of Medicine

Date:     April 27, 2017

We are pleased to share with you an important milestone for the Harrington Discovery Institute at University Hospitals, part of The Harrington Project for Discovery & Development. The Harrington Discovery Institute and Takeda Pharmaceutical Company are today announcing a multi-year collaboration to accelerate breakthrough discoveries in rare diseases.

This collaboration will build on Harrington Discovery Institute’s established operating model and create a new program called the Takeda-Harrington Scholar Program for Rare Diseases. Through this partnership, the Takeda-Harrington Program will provide funding and hands-on drug development guidance to US MD and PhD scientists whose discoveries show promise for translation into novel treatments for rare diseases.

Refer to today’s news release for more information about this exciting new partnership. If you have questions, please contact Natalie Haynes, Harrington Discovery Institute Program Director, at